| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
41,954,000 |
| Market
Cap: |
813.91(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.375 - $40.33 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1162 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
85,098 |
359,070 |
| Total Buy Value |
$0 |
$0 |
$1,099,643 |
$11,099,621 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
3 |
4 |
| Total Shares Sold |
31,156 |
37,186 |
52,466 |
274,108 |
| Total Sell Value |
$693,905 |
$838,445 |
$1,291,641 |
$6,831,038 |
| Total People Sold |
1 |
2 |
4 |
6 |
| Total Sell Transactions |
2 |
4 |
7 |
27 |
| End Date |
2025-06-19 |
2025-03-18 |
2024-09-17 |
2023-09-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Renton Hollings |
|
– • – |
2025-08-08 |
4 |
AS |
$19.44 |
$200,714 |
D/D |
(10,231) |
4,965 |
|
11% |
|
| Renton Hollings |
|
– • – |
2025-08-08 |
4 |
OE |
$6.93 |
$70,901 |
D/D |
10,231 |
15,196 |
|
- |
|
| Renton Hollings |
|
– • – |
2025-07-02 |
4 |
AS |
$23.09 |
$493,191 |
D/D |
(20,925) |
4,965 |
|
-2% |
|
| Renton Hollings |
|
– • – |
2025-07-02 |
4 |
OE |
$6.93 |
$145,010 |
D/D |
20,925 |
25,890 |
|
- |
|
| Fenton Dennis M |
|
– • – |
2025-06-18 |
4 |
AS |
$23.97 |
$72,270 |
D/D |
(3,015) |
4,965 |
|
0% |
|
| Renton Hollings |
|
– • – |
2025-06-18 |
4 |
AS |
$23.97 |
$72,270 |
D/D |
(3,015) |
4,965 |
|
0% |
|
| Jain Rita |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,330 |
11,864 |
|
- |
|
| Ware J. Anthony |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,030 |
13,530 |
|
- |
|
| Renton Hollings |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,030 |
7,980 |
|
- |
|
| Schmid John P. |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,030 |
52,267 |
|
- |
|
| Marquet Magda |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,030 |
9,930 |
|
- |
|
| Fenton Dennis M |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,030 |
7,980 |
|
- |
|
| Orwin John A |
|
– • – |
2025-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,030 |
9,365 |
|
- |
|
| Schmid John P. |
|
– • – |
2025-03-25 |
4 |
A |
$18.18 |
$201,241 |
I/I |
11,068 |
11,068 |
|
- |
|
| Schmid John P. |
|
– • – |
2025-01-13 |
4 |
OE |
$4.55 |
$275,007 |
D/D |
42,337 |
46,237 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-06 |
4 |
D |
$15.30 |
$31,426 |
D/D |
(2,054) |
13,802 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,245 |
15,856 |
|
- |
|
| Faga Daniel |
President, CEO |
• • – |
2025-01-06 |
4 |
D |
$15.30 |
$97,721 |
D/D |
(6,387) |
436,466 |
|
- |
|
| Faga Daniel |
President, CEO |
• • – |
2025-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,850 |
442,853 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2025-01-06 |
4 |
D |
$15.30 |
$34,593 |
D/D |
(2,261) |
25,643 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2025-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,145 |
27,904 |
|
- |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2025-01-06 |
4 |
D |
$15.30 |
$33,920 |
D/D |
(2,217) |
11,003 |
|
- |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2025-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,545 |
13,220 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-03 |
4 |
D |
$14.60 |
$49,742 |
D/D |
(3,407) |
10,611 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,293 |
14,018 |
|
- |
|
195 Records found
|
|
Page 1 of 8 |
|
|
0.76 (3.77%) 
